advances in breast carcinoma management leading to earlier detection of disease and the development of more effective treatments resulting in significant decline in breast carcinoma deaths.
Because the hormonal receptors are well-known predictive factors of the response to the hormonal therapy in mammary carcinoma, their evaluation through imunohistochemical methods is absolutely necessary. The assessment of prognostic factors, in order to provide a prediction of outcome, has become an essential part of the histopathologist's role in the handling and histological reporting of invasive breast carcinomas.
Although many markers have been evaluated, it is well known that ER, PR and HER-2 expression is most useful in predicting response to therapy. In English literature it is documented that the expression of ER and PR is low in Asian countries when compared to that of Western countries. HER2/neu over expression is uniform throughout the world. Studies have shown that triplenegative breast carcinomas are aggressive, likely to spread beyond the breast and recur after treatment.
In the present study an attempt was made to evaluate the expression of HER-2/neu, Estrogen Receptor (ER) and Progesterone Receptors (PR) in breast carcinoma and to compare it with other prognostic parameters such as histological type and grade, tumor size, patients' age, and lymph node metastases.
METHODS
This is a prospective study for a period of two years at the department of Pathology, in a tertiary care centre. We received 111 mastectomy specimens during this period out of which 52 patients were funded under Arogyasri and were subjected for ER, PR, HER2/neu receptor study.
Specimens were thoroughly grossed according to standard protocol. The following data was recordedtumor size, infiltration of the tumor to nipple and areola, posterior margin, adjacent breast changes, number of lymph nodes involved and size of lymph nodes. Relevant clinical data and demographic particulars were recorded.
Tissue was subjected to routine processing and sections were stained with H&E. The histopathological sections were diagnosed basing on WHO classification, and graded adopting Modified Blooms Richardson grading system.
The paraffin blocks were subjected to ER, PR, HER 2/neu receptor study.
Specimens have been processed by the HRP polymer method. Protein retrieval has been done by microwave technique. The following antibody clones have been used.1. Mouse anti-human estrogen receptor alpha clone 1D5, 2. Mouse anti-human progesterone receptor clone PgR636, 3. Rabbit anti-human c-erb-2 oncoprotein.
Staining pattern for ER and PR is confined to the nucleus. A positive staining is defined when more than 10% of cells take up the nuclear stain of any intensity. Breast ductal epithelial cells act as internal controls. Staining pattern for HER2/neu is confined to the cell membrane. The staining pattern was compared with the control slides provided by the company ER, PR staining was quantified by using Allred score. 12 All the slides were quantified by giving proportional score based on the percentage of cells showing nuclear stain and intensity score based on intensity of staining.
The Proportional Score (PS) is as follows: Figure 3, 4) . In 27/41 (65.8%) showed negative expression of both ER and PR. One case each showed ER positive and PR negative expression and ER negative and PR positive expression. 10/41 (24.3%) showed HER2/neu membrane positivity with score of 2+ meaning equivocal reaction, which has to be confirmed by FISH. HER2/neu membrane positivity with score 3 is shown in 5/31 (16.1%) ( Figure 5 ) and negative expression in 16/31 (51.61%) of cases (Table 3) .
On correlating ER and PR expression of infiltrating ductal carcinoma with various clinico-pathological parameters, the observations in the present study was that ER, PR positive expression has no association with age and size of tumor. Their expression was higher in grade 1 tumors 10/12 (83.3%). The ER,PR negative expression was more in size of tumor being greater than 2 cm; 25/27 (92.5%), positive lymph nodes 14/27 (51.8%) and stage II and stage III tumors being 26/27 (96.2%) ( Table 4 ). (Table  7) . Medullary carcinoma (Figure 6 ), mucinous carcinoma ( Figure 9 ) tubular carcinoma are grade 1 tumors and more commonly seen beyond 45 years of age 8/11 (72.7%). One case of male breast carcinoma was seen with histopathological diagnosis of tubular carcinoma ( Figure 11 , 12, 13, 14, 15). The tumor size was more than 2 cm in all these cases. 9/11 (81.8%) were negative for lymph nodes with 2 cases showing metastatic lymph nodes. 10/11 (90.9%) presented with stage II disease ( Table 8) .
Triple negative receptor expression was seen in metaplastic carcinoma, invasive papillary carcinoma ( Figure 10 ) and invasive lobular carcinoma (Figure 8 ). In the English literature medullary carcinoma is negative for HER2/neu expression but in the present study in 2 cases the expression for HER2/neu was positive (Table 9 ) (Figure 7 ). 
DISCUSSION
Breast cancer accounts for 19-34% of all cancer cases among women nationally. As per the data from national and regional cancer registries, it is the commonest cancer and is listed as the second leading site among women. The age-standardized incidence rates vary from 9-28.6 per 100000 women, the lowest being from the rural areabased registry Barshi. The majority of the patients seek medical advice when the disease is fairly advanced. Early breast carcinoma constitutes only 30% of the breast cancer cases seen at regional cancer centers in India, whereas it constitutes 60-70% of cases in the developed world. There is no prospective or retrospective published case series on early carcinoma of breast from India. There is a paucity of data regarding breast carcinoma in the developing world; hence individual institutes should have the knowledge of the various clinico-pathological parameters of carcinoma breast specific for their region.
In the present study 52 mastectomy cases were assessed for clinico-pathological parameters and for expression of estrogen, progesterone receptors and over expression of human epidermal growth factor receptor 2. Out of 52 cases of carcinoma breast 41 (78.8%) were infiltrating duct cell carcinoma and other variants were 11 (21.1%).
Clinico-pathological parameters in infiltrating ductal carcinoma
In the present study the mean age at presentation of carcinoma breast was 51.5 years. 54% of cases occurred in the post-menopausal age group with 46% occurring less than 45 years of age. In the study by Lobna Ayadi et al. 1 51.6% of cases occurred in less than 50 years of age with median age of 51 years and 46% of cases occurred in less than 45 years. In the study by Vinod Raina et al. 2 49.7% of cases occurred in less than 45 years and 48.5% cases in greater than 45 years. In the study by Sunita Saxena et al. 3 of New Delhi reported that the median age of occurrence of carcinoma breast was 47.8 years.
In English literature one of the major risk factor for carcinoma breast is nulliparity. In the present study out of 52 cases only one case had history of nulliparity and two cases were men with carcinoma breast. Women with less than or equal to two children were 80.4% and more than two children were 14.6%.The size of the tumor greater than 2 cm in the present study was 90% and less than 2cm was 10%.In the study by Menaka DS. Lokuhetty et al. 4 58% cases had size of tumor more than 2 cm. Lobna Ayadi et al. 1 documented in their study that in 12.9% the size of tumor was less than 2cm and in 87% greater than 2 cm. Lakmini KB. Mudduwa et al. 5 in their study reported that 14.5% of tumors was less than 2 cm and in 85.5% the tumor was more than 2 cm. In the study by Zubair Ahmed et al. 6 the tumor size was less than 2 cm in 7.5% of cases and 92.4% of cases with tumor size more than 2 cm.
The commonest histological type was infiltrating duct cell carcinoma (NOS) type constituting 78.8% of cases in the present study. In the studies by Vinod Raina et al., 2 Menaka DS. Lokuhetty. 4 Lobna Ayadi et al. 1 were 92.8%, 86.3% and 83.8% respectively. Infiltrating duct cell carcinoma is graded using modified Bloom Richardson grading system into three grades. In the present study grade 1 tumors were 68.2%, grade 2 tumors were 21.9% and 9.75% tumors were grade 3. In the study by Zubair Ahmed et al. 6 of Karachi Pakistan documented 4.17 % as grade 1 tumors, grade 2 were 75.83% and grade 3 tumors as 20%. Lakmini KB. Mudduwa et al. 5 reported 14.6% as grade 1 tumors, 36.4% as grade 2 tumors and 49% as grade 3 tumors. The grade 1, grade 2 and grade 3 tumors in the study by Lobna Ayadi et al. 1 was 10.9%, 63.2% and 25.8%.
In the present study lymph node metastasis in infiltrating duct cell carcinoma was seen in 53.6% of cases and negative for metastasis in 46.3% of tumors. In 72.7% of cases the size of lymph nodes was less than 2 cm with 27.2% showing lymph node size of more than 2 cm. The number of lymph nodes positive for metastasis, less than 4 in number was 55% and those more than 4 were 45%. In the studies by various authors like Zubair Ahmed et al., 6 Lakmini KB. Mudduwa et al., 5 Seho Park et al., 7 Lobna Ayadi et al. 1 and Menaka DS. Lokuhetty 4 documented lymph nodes positive for metastasis as 74.77%, 57.7%, and 27.8%, 65% and 41% respectively. Vascular invasion was seen in 26.8% of cases in the present study and out of these cases with vascular invasion, 81.8% of cases showed lymph node metastatic deposits. In the study by Zubair Ahmed et al. 6 vascular invasion was seen in 35.8% of cases. Tumor necrosis was seen in 39% of cases in the present study and commonly associated with moderate and high grade tumors. In these cases with tumor necrosis lymph node metastasis was seen in 62.5% of cases with 60% of the involving more than 4 lymph nodes. In the study by Zubair Ahmed et al. 6 tumor necrosis was seen in 63.33 % of cases.
In the present study 63.4% of the tumors presented in stage II disease, 29.2% in stage III disease and 7.3% in stage I disease. In the study by Vinod Raina et al. 2 stage III tumors were 35.2%.
Clinico-pathological parameters in other variants of carcinoma breast
In the present study medullary carcinoma constituted 7.69%, tubular carcinoma 3.8%, invasive lobular carcinoma 1.9%, metaplastic carcinoma 3.8%, invasive papillary carcinoma 1.9% and mucinous carcinoma in 1.9% of cases. Vinod Raina et al. 2 documented 2.9% of lobular carcinoma, medullary carcinoma 1.4% and Lobna Ayadi et al. 1 reported 3, 8% of invasive lobular carcinoma, 3.2% mucinous carcinoma and 0.6% as metaplastic carcinoma. In the present study a case of tubular carcinoma and a case of infiltrating duct cell carcinoma was seen in male breast. These non-ductal tumors were more common in the age group of more than 45 years (72.7%). All the cases showed tumor size of more than 2 cm. Eighty one percent of cases did not show lymph node metastasis and 90.9% of cases presented in stage II. ER+/PR+/HER2/neu-; 68.9%, ER-/PR-/HER2/neu+; 7.5%, triple negative in 13.4% of cases. In the study by Lobna Ayadi et al. 1 the ER-/PR-/HER2/neu+ was 33.3% and triple negative in 21.9% of cases. Aye Thike et al. 10 reported triple negative cases as 13% in their study.
Hormonal
On analyzing these triple negative cases 38.7% were seen in age greater than 45 years, 51.6% with tumor size greater than 2 cm, 29% cases showing lymph node metastasis. In 55.5% of cases with positive nodes more than 4 lymph nodes involved. Thirty nine percent tumors were grade1 and 51.6% of tumors were in stage II and stage III disease. The molecular subtypes in the present study were luminal type A constituted 26.8%, Basal like 41.4% and HER2/neu type was 12.1%.
Estrogen receptor negative and triple negative breast carcinoma carry poor prognosis and are not amenable to hormone therapy. It is observed in literature that Indian patients with carcinoma breast have a higher tendency to have these with negative expression, which is also observed in the present study. Suraj Manjunath et al.
his study has documented the probable reasons for occurrence of such tumors with variable biological behavior. He suggested that the patients in India are about one decade younger than that of the west, which contributes to high ER negativity as younger patients tend to have more ER negative and more triple negative tumors. In India the patients often present at advanced stage of breast carcinoma, in which ER negativity is likely to be higher.
CONCLUSION
Infiltrating duct cell carcinoma (NOS) type was the commonest type of carcinoma breast in our institute with significant group occurring in less than 45 years of age. 95 % of women were multipara with two or more children. ER and PR positive expression was seen in grade 1 tumors and negative expression was seen with tumor size more than 2cm, positive lymph nodes and higher stage of disease. HER2/neu negative expression was seen in the post-menopausal age group, tumor size more than 2 cm, positive lymph nodes and higher stage of disease indicating bad prognosis. HER2/neu expression was inversely related to ER and PR expression. HER2/neu expression was seen in 50% of medullary carcinoma which is rare. Triple negative cases were seen in 54.8% cases of infiltrating duct cell carcinoma indicating bad prognosis.
